KYSE-450

Cat.No.: CSC-C0435

Species: Homo sapiens (Human)

Source: Esophagus

Morphology: epitheloid cells growing adherently as monolayers

Culture Properties: monolayer

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C0435

Description

Established from the well differentiated invasive eosphageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 59-year-old Japanese man prior to treatment (depth of invasion was not beyond the submucosa); described as carrying p53 mutation and amplification of the oncogene MYC

Species

Homo sapiens (Human)

Source

Esophagus

Recommended Medium

90%RPMI1640 or 45%RPMI1640 + 45%Ham's F-12 + 10%h.i. FBS.

Culture Properties

monolayer

Morphology

epitheloid cells growing adherently as monolayers

Karyotype

Human hyperdiploid karyotype with 6.7% polyploidy - 57(49-57)<2n>, -Y, +1, +3, +3, +7, +12, +17, -18, +7mar, der(1)t(1;6)(p22;q11), add(1)(p32/34), del(2)(p23), del(3)(p22), del(4)(q21), add(5)(q35), del(6)(q25), add(7)(p22), add(8)(p23), add(9)(q34), del

Disease

Esophageal Squamous Cell Carcinoma

Quality Control

Mycoplasma: contamination was eliminated with BM-Cyclin (tiamulin & minocycline), then negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 +, cytokeratin-18 +, cy

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 3 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Synonyms

KYSE 450; KYSE450; Kyse450

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

KYSE-450 is an immortalized human esophageal squamous cell carcinoma (ESCC) cell line that was isolated in 1990 from a poorly differentiated thoracic ESCC lesion of a male patient. Morphologically, KYSE-450 cells have an epithelial-like morphology, with polygonal or irregular shapes, clear cell borders, high nuclear to cytoplasmic ratio, and prominent nucleoli - typical features of malignant epithelial cells. The cells are grown as adherent monolayers in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Standard culture conditions (37°C, 5% CO₂) produce doubling times of 36-48 hours for the cell population while proper maintenance allows stable growth for more than 50 passages.

Functionally, KYSE-450 cells express typical molecular markers associated with ESCC (e.g., cytokeratins 14 and 19) and contain genomic mutations commonly observed in ESCC (e.g., TP53 mutation, CDKN2A deletion) that underlie their malignant phenotypes, such as uncontrolled proliferation and invasive behavior. As a result, KYSE-450 cells are broadly utilized in studies investigating the pathogenesis of ESCC, for screening of chemotherapeutic (e.g., cisplatin, 5-fluorouracil) and targeted therapeutics and mechanisms of resistance, and for in vitro and in vivo (xenograft) studies of ESCC metastasis and tumor-stroma interactions.

Morphology of cells grown in RMPI 1640 medium supplemented with 10% FBS. — Fig. 1. Morphology of cells grown in RMPI 1640 medium supplemented with 10% FBS (Lv Z, *et al.*, 2017).

Novel Chalcone Analog Ch-19 Effectively Inhibited ESCC Proliferation In Vitro

Esophageal cancer is characterized by a poor prognosis and low five-year survival rate. Chalcone, a flavonoid, has demonstrated anti-tumor properties in various cancers, but its derivatives' effects on esophageal squamous cell carcinoma are underexplored. In this study, Yang's team designed and synthesized novel chalcone analogs, selecting Ch-19 for its potent anti-tumor activity. They assessed Ch-19's effects on KYSE-450 and Eca-109 esophageal cancer cells (ESCC). CCK-8 assay demonstrated that mean IC₅₀ values of the twenty compounds against both ESCC cells varying from 4.97 to 56.39 µM and 9.43 to 67.40, respectively (Fig. 1B). Notably, Ch-19 exerted the strongest anti-tumor activity against ESCC cells (Fig. 1C), which may be attributed to the substitution of the methoxy group of aromatic ketones and the 4-substitution nitro group of aromatic aldehydes. Moreover, the cell viability was significantly reduced after Ch-19 treatment in both ESCC cells in a dose and time-dependent manner (Fig. 1D-E). The mean IC₅₀ values in KYSE-450 and Eca-109 cells were 4.97 µM and 9.43 µM, respectively.

Inhibitory effect of 20 chalcone derivatives against ESCC cells in vitro. — Fig. 1. Inhibitory effect of 20 chalcone derivatives against ESCC cells *in vitro* (Yang Y, Wu H, *et al.*, 2022).

Compound W478 Inhibits the Proliferation of Esophageal Cancer Cell

Esophageal cancer is a serious malignancy with a poor prognosis and high mortality rate. Serine hydroxymethyltransferase 2 (SHMT2) has emerged as a promising target for esophageal cancer therapy. Akram et al. investigated the potential of compound W478, a novel SHMT2 inhibitor, to serve as a lead compound for developing treatments for esophageal carcinoma.

The antiproliferative activity of compound W478 on esophageal cancer cells was assessed using the CCK-8 assay. Results showed that W478 significantly inhibited cell proliferation, with IC₅₀ values of 1.62 μM for KYSE-450 and 1.18 μM for KYSE-70 cells (Fig. 2A and B). A colony formation assay further demonstrated that W478 reduced the number and size of colonies in a dose-dependent manner (Fig. 2C-F). The moderate dose (5 μM) significantly decreased colony numbers, while the maximum dose (10 μM) nearly halted cell growth. These findings indicate that W478 suppresses the clonogenic capacity of KYSE-450 and KYSE-70 cells, supporting its potential as a treatment for esophageal cancer. Additionally, W478's cytotoxicity was tested against HET-1 A and BEAS-2B cells, revealing IC₅₀ values of 7.38 μM and 1.36 μM, respectively, indicating poor selectivity between cancer and normal cells.